Q-omics provides the consensus-scored FLNC profile across patient tissues and cancer cell-line models. FLNC expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FLNC is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, FLNC protein abundance shows 26,623 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight LUSC, BLCA, and UCEC as cancer lineages where FLNC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLNC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLNC survival associations across molecular data types. FLNC RNA expression shows survival associations in the most cancer types (28), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLNC RNA expression–survival associations across cancer types. High FLNC expression shows unfavorable associations in LUSC, UVM, BLCA, LUAD, KIRC and MESO. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for FLNC RNA expression.
This table summarizes FLNC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FLNC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLNC shows lower tumor expression in BLCA, THCA, COAD, UCEC and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher FLNC RNA expression in normal versus tumor tissue (log2 FC = −6.700, t-test p < 0.001).
This table shows molecular features associated with FLNC in patient tissues and cancer cell lines. In patient samples, FLNC shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, FLNC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
